What I said was one patient per site PER YEAR.
Facts:
> trevear sparsentan phase3 fgs trial got 371 patients
> from their paper, it took 33 months (April 2018 to Jan 2021) to screen & randomise the 371
> they operated in 225 sites, check the excellent interactive map on clinical trials. gov for their trial as proof
> my math tell me that’s 1.65 patients per site over 33 months or about 0.6 patients per site per year
so if anything dimerx is doing a bit better than traverea.
What I said was one patient per site PER YEAR.Facts: > trevear...
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $280.6M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 54.5¢ | 51.0¢ | $1.715M | 3.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 365433 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 19658 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |